Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients

Cancer

Volumn 118, Issue 17, 2012, Pages 4321-4330

  Christensen, Anthony M ^a   Pauley, Jennifer L ^a,b   Molinelli, Alejandro R ^a   Panetta, John C ^a,b   Ward, Deborah A ^a,b   Stewart, Clinton F ^a,b   Hoffman, James M ^a,b   Howard, Scott C ^a,c   Pui, Ching Hon ^a,c   Pappo, Alberto S ^a,c   Relling, Mary V ^a,b,c   Crews, Kristine R ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

carboxypeptidases; compassionate use trials; gamma glutamyl hydrolase; methotrexate administration and dosage; methotrexate adverse effects; pediatric; renal insufficiency chemically induced

Indexed keywords

CARBOXYPEPTIDASE G2; CREATININE; METHOTREXATE;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER PATIENT; CANCER RELAPSE; CHILD; CHILDHOOD CANCER; CLINICAL EVALUATION; CLINICAL STUDY; COHORT ANALYSIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HODGKIN DISEASE; HUMAN; KIDNEY FUNCTION TEST; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONLYMPHOBLASTIC LYMPHOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; URINE VOLUME;

ACUTE KIDNEY INJURY; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HUMANS; MALE; METHOTREXATE; RETREATMENT; YOUNG ADULT;

EID: 84862565928     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27378     Document Type: Article

References (31)

1. Treon SP, Chabner BA,. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996; 42: 1322-1329.
2. Widemann BC, Adamson PC,. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006; 11: 694-703.
3. Patterson DM, Lee SM,. Glucarpidase following high-dose methotrexate: update on development. Expert Opin Biol Ther. 2010; 10: 105-111.
4. Park ES, Han KH, Choi HS, Shin HY, Ahn HS,. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer Res Treat. 2005; 37: 133-135.
5. Schwartz S, Borner K, Muller K, et al. Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist. 2007; 12: 1299-1308.
6. Snyder RL,. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm. 2007; 64: 1163-1169.
7. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004; 100: 2222-2232.
8. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005; 92: 480-487.
9. DeAngelis LM, Tong WP, Lin S, Fleisher M, Bertino JR,. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol. 1996; 14: 2145-2149.
10. Esteve MA, Devictor-Pierre B, Galy G, et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol. 2007; 63: 39-42.
11. Hum M, Kamen BA,. Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. Pediatr Hematol Oncol. 1995; 12: 521-524.
12. Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma. 2002; 43: 2139-2143.
13. Mohty M, Peyriere H, Guinet C, Hillaire-Buys D, Blayac JP, Rossi JF,. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk Lymphoma. 2000; 37: 441-443.
14. Nowicki TS, Bjornard K, Kudlowitz D, Sandoval C, Jayabose S,. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report. J Pediatr Hematol Oncol. 2008; 30: 950-952.
15. O'Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc. 1996; 71: 161-165.
16. Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D,. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004; 38: 422-427.
17. Sieniawski M, Rimpler M, Herrmann R, Josting A,. Successful carboxypeptidase G2 rescue of a high-risk elderly Hodgkin lymphoma patient with methotrexate intoxication and renal failure. Leuk Lymphoma. 2007; 48: 1641-1643.
18. Tuffaha HW, Al Omar S,. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2011; 17: 136-140.
19. Vilay AM, Mueller BA, Haines H, Alten JA, Askenazi DJ,. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase. Pharmacotherapy. 2010; 30: 111.
20. Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010; 28: 3979-3986.
21. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997; 15: 2125-2134.
22. Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004; 96: 1557-1559.
23. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC,. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995; 76: 521-526.
24. Zoubek A, Zaunschirm HA, Lion T, et al. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol. 1995; 12: 471-477.
25. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986; 314: 471-477.
26. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994; 12: 1667-1672.
27. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA,. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297: 630-634.
28. Pinedo HM, Zaharko DS, Bull JM, Chabner BA,. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976; 36: 4418-4424.
29. Flombaum CD, Meyers PA,. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17: 1589-1594.
30. Steinborner S, Henion J,. Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal Chem. 1999; 71: 2340-2345.
31. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.